cyproterone acetate has been researched along with Bone Cancer in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (14.29) | 18.7374 |
| 1990's | 9 (64.29) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bangma, CH; Bratus, D; Fiala, R; Kukk, L; Mickisch, GH; Pagi, H; Schröder, FH; Verhagen, PC; Verkerk, AM; Vjaters, E; Wildhagen, MF | 1 |
| Bagatini, MD; Battisti, IE; Battisti, V; Chiesa, J; Duarte, MM; Gonçalves, JF; Maders, LD; Morsch, VM; Reetz, LG; Schetinger, MR | 1 |
| Collette, L; de Reijke, TM; Schröder, FH | 1 |
| Cooper, EH; Purves, D; Whelan, P | 1 |
| Jørgensen, LH; Jørgensen, T; Tveter, KJ | 1 |
| Danielsen, HE; Jørgensen, T; Kaalhus, O; Müller, C; Tveter, KJ | 1 |
| Azmatullah, S; Fellows, GJ; Gingell, JC; O'Boyle, PJ; Thorpe, SC | 1 |
| Collins, BJ; Murphy, BJ | 1 |
| de Voogt, H; Denis, L; Sylvester, RJ | 1 |
| Bonnesen, T; Frimodt-Møller, C; Nilsson, T; Ostri, P | 1 |
| Becker, M; Goldschmidt, AJ; Peter, K; Tunn, UW | 1 |
| D'Eramo, G; Di Silverio, F; Sciarra, F; Serio, M | 1 |
| Barasolo, E; de Pauw, M; de Voogt, HJ; Lardennois, B; Pavone-Macaluso, M; Sylvester, R; Viggiano, G | 1 |
| Arvis, G; Tobelem, G | 1 |
9 trial(s) available for cyproterone acetate and Bone Cancer
| Article | Year |
|---|---|
Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial.
Topics: Aged; Androgen Antagonists; Bone Neoplasms; Cyproterone Acetate; Humans; Male; Prostatic Neoplasms | 2014 |
Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Cyproterone Acetate; Disease Progression; Flutamide; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Sensitivity and Specificity; Soft Tissue Neoplasms; Survival Analysis | 2003 |
Total androgen suppression: experience from the Scandinavian Prostatic Cancer Group Study No. 2.
Topics: Bone Neoplasms; Cyproterone Acetate; Double-Blind Method; Humans; Male; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Survival Rate | 1993 |
Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer. Experience from the Scandinavian Prostatic Cancer Group Study No. 2 (SPCG-2).
Topics: Androgen Antagonists; Bone and Bones; Bone Neoplasms; Combined Modality Therapy; Cyproterone Acetate; Disease Progression; Follow-Up Studies; Humans; Male; Orchiectomy; Prognosis; Prospective Studies; Prostatic Neoplasms; Radionuclide Imaging; Severity of Illness Index | 1995 |
A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyproterone Acetate; Disease Progression; Goserelin; Humans; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms; Safety | 1996 |
The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Combined Modality Therapy; Cyproterone Acetate; Disease-Free Survival; Flutamide; Goserelin; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Orchiectomy; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Risk Assessment; Survival Rate | 1998 |
Treatment of symptomatic metastatic prostatic cancer with cyproterone acetate versus orchiectomy: a prospective randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Cyproterone; Cyproterone Acetate; Humans; Male; Middle Aged; Orchiectomy; Palliative Care; Prospective Studies; Prostatic Neoplasms | 1991 |
Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study.
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Cyproterone; Cyproterone Acetate; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Prostatic Neoplasms; Testosterone | 1990 |
Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological
Topics: Aged; Bone Neoplasms; Carcinoma; Cardiovascular Diseases; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Europe; Follow-Up Studies; Humans; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Prostatic Neoplasms; Random Allocation | 1986 |
5 other study(ies) available for cyproterone acetate and Bone Cancer
| Article | Year |
|---|---|
Oxidative stress and antioxidant status in prostate cancer patients: relation to Gleason score, treatment and bone metastasis.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Ascorbic Acid; Bone Neoplasms; Catalase; Cyproterone Acetate; Erythrocytes; Goserelin; Humans; Lipid Peroxidation; Male; Middle Aged; Neoplasm Grading; Oxidative Stress; Prostatic Neoplasms; Protein Carbonylation; Sulfhydryl Compounds; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances; Vitamin E | 2011 |
Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers, Tumor; Bone and Bones; Bone Neoplasms; Cyproterone Acetate; Diethylstilbestrol; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Isoenzymes; Male; Middle Aged; Monitoring, Physiologic; Neoplasm Staging; Orchiectomy; Probability; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Sensitivity and Specificity; Time Factors | 1994 |
Severe hepatitis and liver failure induced by cyproterone acetate.
Topics: Aged; Androgen Antagonists; Bone Neoplasms; Chemical and Drug Induced Liver Injury; Cyproterone Acetate; Humans; Liver Cirrhosis; Liver Failure; Liver Function Tests; Male; Prostatic Neoplasms | 1996 |
Initial treatment of prostatic cancer by endocrine measures and cytotoxic drugs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Fluorouracil; Humans; Male; Neoplasm Staging; Orchiectomy; Prostatic Neoplasms; Survival Rate | 1990 |
[Cyproterone acetate. Its value in the treatment of prostatic cancer. Apropos of 45 cases].
Topics: Acid Phosphatase; Androgen Antagonists; Bone Neoplasms; Cyproterone; Cyproterone Acetate; Follow-Up Studies; Humans; Male; Neoplasm Staging; Prostatic Neoplasms; Radionuclide Imaging; Retrospective Studies | 1988 |